17 Apr 2026
Three Victorians charged after $2 million steroid and peptide seizure
Three Victorians have been charged after a major investigation into the illegal import of performance and image enhancing drugs in Melbourne.
17 Apr 2026
$1.8M Worth of Illegal Vapes Seized in Sydney Crackdown
More than 30,000 illegal vaping products have been seized in a major enforcement operation in south-west Sydney.
08 Apr 2026
TGA Seeks Feedback on Removing Andrographis from Low-Risk Medicines List
The Therapeutic Goods Administration (TGA) has started a consultation on whether to remove Andrographis paniculata from the list of low-risk ingredients used in listed medicines.
26 Mar 2026
TGA Issues Fines to Health Practitioners for Unapproved Imports
The Therapeutic Goods Administration (TGA) has issued six infringement notices totalling $23,760 to three health practitioners for allegedly importing unapproved therapeutic goods without permission, breaching the Therapeutic Goods Act 1989.
26 Mar 2026
TGA Seeks Public Feedback on Sunscreen Regulation
The Therapeutic Goods Administration (TGA) has opened an 8-week public consultation to improve how sunscreens are regulated in Australia.
10 Feb 2026
Authorities Seize Thousands of Illegal Vapes in Sydney
Authorities have seized more than 57,000 illegal vaping products during a major crackdown in Burwood, NSW.
02 Feb 2026
TGA Issues Infringement Notices to Prime Medic Group Over Weight Loss Medicine Advertising
The Therapeutic Goods Administration (TGA) has issued infringement notices to Prime Medic Group Pty Ltd
29 Jan 2026
TGA Takes Action Against Unapproved Therapeutic Goods
The Therapeutic Goods Administration (TGA) has issued 11 fines totalling $43,560 to six people for allegedly importing unapproved therapeutic products and advertising them unlawfully
23 Jan 2026
ACCM Meeting Statement – Meeting 38, 6 November 2025
ACCM Meeting Statement – Meeting 38, 6 November 2025
22 Jan 2026
TGA Updates Compliance Principles for 2026–2027
The Therapeutic Goods Administration (TGA) has released its compliance principles for the next two years, reinforcing a risk-based approach to monitoring and enforcing regulations for therapeutic goods.